These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 15358444

  • 1. Twenty-four hour growth hormone secretion in patients with panic disorder.
    Abelson JL, Curtis GC, Uhde TW.
    Psychoneuroendocrinology; 2005 Jan; 30(1):72-9. PubMed ID: 15358444
    [Abstract] [Full Text] [Related]

  • 2. Growth-hormone response to clonidine in panic disorder patients in comparison to patients with major depression and healthy controls.
    Gann H, Riemann D, Stoll S, Berger M, Müller WE.
    Pharmacopsychiatry; 1995 May; 28(3):80-3. PubMed ID: 7568369
    [Abstract] [Full Text] [Related]

  • 3. HPA axis activity in patients with panic disorder: review and synthesis of four studies.
    Abelson JL, Khan S, Liberzon I, Young EA.
    Depress Anxiety; 2007 May; 24(1):66-76. PubMed ID: 16845643
    [Abstract] [Full Text] [Related]

  • 4. 24-hour pituitary and adrenal hormone profiles in chronic fatigue syndrome.
    Di Giorgio A, Hudson M, Jerjes W, Cleare AJ.
    Psychosom Med; 2005 May; 67(3):433-40. PubMed ID: 15911907
    [Abstract] [Full Text] [Related]

  • 5. Altered nocturnal growth hormone (GH) secretion in obsessive compulsive disorder.
    Kluge M, Schüssler P, Weikel J, Dresler M, Zuber V, Querfurt F, Yassouridis A, Steiger A.
    Psychoneuroendocrinology; 2006 Oct; 31(9):1098-104. PubMed ID: 16965859
    [Abstract] [Full Text] [Related]

  • 6. Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects.
    Abelson JL, Liberzon I, Young EA, Khan S.
    Arch Gen Psychiatry; 2005 Jun; 62(6):668-75. PubMed ID: 15939844
    [Abstract] [Full Text] [Related]

  • 7. Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers.
    Uhde TW, Tancer ME, Rubinow DR, Roscow DB, Boulenger JP, Vittone B, Gurguis G, Geraci M, Black B, Post RM.
    Neuropsychopharmacology; 1992 Feb; 6(2):101-18. PubMed ID: 1610485
    [Abstract] [Full Text] [Related]

  • 8. Anxious and depressive disorders and their comorbidity: effect on central nervous system noradrenergic function.
    Cameron OG, Abelson JL, Young EA.
    Biol Psychiatry; 2004 Dec 01; 56(11):875-83. PubMed ID: 15576065
    [Abstract] [Full Text] [Related]

  • 9. Cranially irradiated adult cancer survivors may have normal spontaneous GH secretion in the presence of discordant peak GH responses to stimulation tests (compensated GH deficiency).
    Darzy KH, Thorner MO, Shalet SM.
    Clin Endocrinol (Oxf); 2009 Feb 01; 70(2):287-93. PubMed ID: 18673465
    [Abstract] [Full Text] [Related]

  • 10. Cognitive style, alprazolam plasma levels, and treatment response in panic disorder.
    Uhlenhuth EH, Starcevic V, Qualls C, Antal EJ, Matuzas W, Javaid JI, Barnhill J.
    Depress Anxiety; 2008 Feb 01; 25(8):E18-26. PubMed ID: 17960759
    [Abstract] [Full Text] [Related]

  • 11. Noradrenergic function in pathological gambling: blunted growth hormone response to clonidine.
    Pallanti S, Bernardi S, Allen A, Chaplin W, Watner D, DeCaria CM, Hollander E.
    J Psychopharmacol; 2010 Jun 01; 24(6):847-53. PubMed ID: 19028836
    [Abstract] [Full Text] [Related]

  • 12. Growth hormone response to clonidine predicts aggression in Alzheimer's disease.
    Herrmann N, Lanctôt KL, Eryavec G, Van Reekum R, Khan LR.
    Psychoneuroendocrinology; 2004 Oct 01; 29(9):1192-7. PubMed ID: 15219643
    [Abstract] [Full Text] [Related]

  • 13. Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder.
    Brambilla F, Perna G, Garberi A, Nobile P, Bellodi L.
    Psychoneuroendocrinology; 1995 Oct 01; 20(1):1-9. PubMed ID: 7838898
    [Abstract] [Full Text] [Related]

  • 14. Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder.
    Coplan JD, Papp LA, Martinez J, Pine D, Rosenblum LA, Cooper T, Liebowitz MR, Gorman JM.
    Am J Psychiatry; 1995 Apr 01; 152(4):619-22. PubMed ID: 7694915
    [Abstract] [Full Text] [Related]

  • 15. A potential role of endogenous progesterone in modulation of GH, prolactin and thyrotrophin secretion during normal menstrual cycle.
    Caufriez A, Leproult R, L'Hermite-Balériaux M, Moreno-Reyes R, Copinschi G.
    Clin Endocrinol (Oxf); 2009 Oct 01; 71(4):535-42. PubMed ID: 19222493
    [Abstract] [Full Text] [Related]

  • 16. Anxiolytic therapy with alprazolam increases muscle sympathetic activity in patients with panic disorders.
    Béchir M, Schwegler K, Chenevard R, Binggeli C, Caduff C, Büchi S, Buddeberg C, Lüscher TF, Noll G.
    Auton Neurosci; 2007 Jul 31; 134(1-2):69-73. PubMed ID: 17363337
    [Abstract] [Full Text] [Related]

  • 17. Acute cortisol administration increases sleep depth and growth hormone release in patients with major depression.
    Schmid DA, Brunner H, Lauer CJ, Uhr M, Yassouridis A, Holsboer F, Friess E.
    J Psychiatr Res; 2008 Oct 31; 42(12):991-9. PubMed ID: 18226817
    [Abstract] [Full Text] [Related]

  • 18. Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs.
    Uhlenhuth EH, Starcevic V, Qualls C, Antal EJ, Matuzas W, Javaid JI, Barnhill J.
    J Clin Psychopharmacol; 2006 Oct 31; 26(5):519-23. PubMed ID: 16974197
    [Abstract] [Full Text] [Related]

  • 19. Relationship between nocturnal growth hormone concentrations, serum IGF-I/IGFBP-3 levels, insulin sensitivity and GH receptor allelic variant in small for gestational age children.
    Mericq V, Román R, Iñiguez G, Angel B, Salazar T, Avila A, Perez-Bravo F, Cassorla F.
    Horm Res; 2007 Oct 31; 68(3):132-8. PubMed ID: 17347571
    [Abstract] [Full Text] [Related]

  • 20. Polysomnographic sleep, growth hormone insulin-like growth factor-I axis, leptin, and weight loss.
    Rasmussen MH, Wildschiødtz G, Juul A, Hilsted J.
    Obesity (Silver Spring); 2008 Jul 31; 16(7):1516-21. PubMed ID: 18464752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.